Leprae

Morbus Hansen — Chronic infectious disease affecting skin, peripheral nerves, mucosa of the upper respiratory tract, and sometimes the eyes.

Aetiology

  • Causative organism: Mycobacterium leprae
    • Acid-fast bacillus, obligate intracellular pathogen
    • Prefers cooler body areas (skin, peripheral nerves, nasal mucosa)
  • Long incubation period: ~2–7 years (can be up to 20 years)
Transmission:
  • Prolonged close contact with untreated cases
  • Nasal droplets (most accepted route)
  • Rare: broken skin contact, zoonotic transmission (armadillos in Americas)

Pathophysiology

  • M. leprae invades Schwann cells → demyelination of peripheral nerves
  • Immune response determines disease spectrum:
    • Strong cell-mediated immunity → Tuberculoid (Paucibacillary)
    • Weak cell-mediated immunity → Lepromatous (Multibacillary)
  • Granuloma formation & nerve damage → sensory loss & deformities

Classification

WHO Clinical Classification

Type
Criteria
Paucibacillary (PB)
1–5 skin lesions, smear (-)
Multibacillary (MB)
>5 lesions, smear (+)

Ridley–Jopling Classification

Spectrum based on immunity:
  1. Tuberculoid (TT) – PB, few lesions, strong immunity
  1. Borderline Tuberculoid (BT)
  1. Borderline Borderline (BB)
  1. Borderline Lepromatous (BL)
  1. Lepromatous (LL) – MB, many lesions, weak immunity

Clinical presentation

General Signs - 5A

  • Achromia Hypopigmented or erythematous patches
  • Alopecia Hair loss over lesions
  • Anesthesia — Sensory loss (pain/temp/touch)
  • Anhidrosis — Loss of sweating
  • Athrophy
  • Peripheral nerve thickening
notion image

Tuberculoid Leprosy

  • Few well-defined patches
  • Asymmetric lesions
  • Early sensory loss prominent
  • Nerve involvement localized

Lepromatous Leprosy

  • Numerous symmetric skin lesions
  • Nodules, diffuse infiltrations
  • "Lion-like face" (leonine facies)
  • Nasal crusting & destruction
  • Symmetric peripheral neuropathy
  • Eyebrow loss (madarosis)

Investigations

Clinical + Laboratory
  • Slit skin smearAcid-fast bacilli (AFB) using Ziehl-Neelsen/Fite-Faraco stain
  • Skin biopsy → granulomas, bacterial load assessment
  • Lepromin test:
    • Positive in tuberculoid
    • Negative in lepromatous

Management

Paucibacillary (PB) — 6 Months

  • Rifampicin 300 mg 2x1 monthly + Dapsone 100 mg 1x1 daily

Multibacillary (MB) — 12 Months

  • Dapsone 100 mg 1x1 daily
  • Rifampicin 300 mg 2x1 monthly
  • Lamprene/Clofazimine 100 mg 3x1 monthly + 50 mg 1x1 daily

Investigations

  • Peripheral neuropathy → deformities
  • Claw hand, foot drop
  • Corneal ulcer → blindness
  • Nasal collapse
  • Secondary infections, ulceration

Reactional States

Immune-mediated inflammatory flares:
Type
Characteristics
Treatment
Type 1 (Reversal reaction)
- Worsening lesions, nerve pain
- PB & MB
- Appear ≤6 months of treatment
- Type IV hypersensitivity
Corticosteroids
Type 2 (ENL – Erythema Nodosum Leprosum)
- Systemic symptoms, painful nodules
- Only MB
- Appear end of treatment
- Type III hypersensitivity
Thalidomide (or steroids)
Reversal Reaction
Reversal Reaction
Ertyhema Nodosum Leprosum
Ertyhema Nodosum Leprosum